预约演示
更新于：2025-09-11
Ferric Maltol
麦芽醇铁
更新于：2025-09-11
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 欧盟 (2016-02-18), |
最高研发阶段(中国)无进展 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H15FeO9 |
InChIKeyAHPWLYJHTFAWKI-UHFFFAOYSA-K |
CAS号33725-54-1 |
关联
17
项与 麦芽醇铁 相关的临床试验NCT05697211
A Pilot Study to Explore Safety, Tolerability and Efficacy of ORal IrON Supplementation with Ferric Maltol in Treating Iron Deficiency and Anaemia in Patients with Heart Failure
NCT05456932
Predicting Response to Iron Supplementation in Patients With Active Inflammatory Bowel Disease
NCT05177484
An Open Label Randomised Trial to Assess the Efficacy of Post-Operative Ferric Maltol Vs Standard Care for Anaemia Following Colorectal Cancer Surgery
100 项与 麦芽醇铁 相关的临床结果
登录后查看更多信息
100 项与 麦芽醇铁 相关的转化医学
登录后查看更多信息
100 项与 麦芽醇铁 相关的专利（医药）
登录后查看更多信息
65
项与 麦芽醇铁 相关的文献（医药）2024-05-01Veterinary microbiology
Streptococcus zooepidemicus in dogs: Exploring a canine pathogen through multilocus sequence typing
Article
作者: Priestnall, Simon L ; Waller, Andrew S ; Mangano, Elli R ; Suarez-Bonnet, Alejandro ; Jones, Gareth M C
Streptococcus equi. subsp. zooepidemicus (S. zooepidemicus) associated diseases in dogs have emerged as a significant concern over recent decades. S. zooepidemicus occurs sporadically in dog populations globally, with increased prevalence in shelters/kennels. This study used multilocus sequence typing (MLST) of 149 independent canine S. zooepidemicus isolates to assess associations between sequence type and breed, country of origin, disease severity, sampling type, year, and behaviour within an outbreak. No clear associations for breed, country, sampling type and year were determined in this study. ST-10 and 123 strains were present within all disease categories, from no clinical signs to severe disease. Assessment of S. zooepidemicus infection in 3 UK outbreaks at the same location found ST-10, 18, 123 strains, and a ST-173 strain in a US outbreak, were associated with haemorrhagic pneumonia and persisted in kennelled populations over time. The ST-173 clonal complex has been noted to have severe virulence capabilities in dogs and other species. S. zooepidemicus seems to thrive in environments with a high risk of transmissibility, overcrowding, stress and naïve populations, particularly for those in shelters/kennels. MLST alone cannot determine the virulence phenotype of S. zooepidemicus in dogs. However, a level of conservancy and diversity within ST allelic loci aids the opportunity to cause severe disease in dogs. Thus, further research into whole genome sequencing and characterising the virulence factors of S. zooepidemicus is warranted in dogs.
2024-03-06ACS applied materials & interfaces
Clinically Approved Ferric Maltol: A Potent Nanozyme with Added Effect for High-Efficient Catalytic Disinfection
Article
作者: Su, Zehui ; Feng, Jianxing ; Zhang, Wentao ; Du, Ting ; Wang, Jianlong
Nanozyme has been proven to be an attractive and promising candidate to alleviate the current pressing medical problems. However, the unknown clinical safety and limited function beyond the catalysis of the most reported nanozymes cannot promise an ideal therapeutic outcome in further clinical application. Herein, we find that ferric maltol (FM), a clinically approved iron supplement synthesized through a facile scalable method, exhibits excellent peroxidase-like activity than natural horseradish peroxidase-like (HRP) and commonly reported Fe-based nanozymes, and also shows high antibacterial performance for methicillin-resistant Staphylococcus aureus (MRSA) elimination (100%) and wound disinfection. In addition, with added effects inherited from contained maltol, FM can accelerate skin barrier recovery. Therefore, the exploration of FM as a safe and desired nanozyme provides a timely alternative to current antibiotic therapy against drug-resistant bacteria.
2024-01-01BMJ open
Predicting response to iron supplementation in patients with active inflammatory bowel disease (PRIme): a randomised trial protocol
Article
作者: van der Meulen-de Jong, Andrea E ; Duijvestein, Marjolijn ; Goetgebuer, Rogier L ; Loveikyte, Roberta ; Mujagic, Zlatan ; Dijkstra, Gerard
Introduction:
Iron deficiency anaemia (IDA) is the most common systemic manifestation of inflammatory bowel disease (IBD) that has detrimental effects on quality of life (QoL) and disease outcomes. Iron deficiency (ID), with or without anaemia, poses a diagnostic and therapeutic challenge in patients with IBD due to the multifactorial nature of ID(A) and its frequent recurrence. Elevated hepcidin—a systemic iron regulator that modulates systemic iron availability and intestinal iron absorption—has been associated with oral iron malabsorption in IBD. Therefore, hepcidin could assist in therapeutic decision-making. In this study, we investigate whether hepcidin can predict response to oral and intravenous iron supplementation in patients with active IBD undergoing anti-inflammatory treatment.
Methods and analysis:
PRIme is an exploratory, multicentre, open-label and randomised trial. All adult patients with active IBD and ID(A) will be assessed for eligibility. The participants (n=90) will be recruited at five academic hospitals within the Netherlands and randomised into three groups (1:1:1): oral ferrous fumarate, oral ferric maltol or intravenous iron. Clinical and biochemical data will be collected at the baseline and after 6, 14 and 24 weeks. Blood samples will be collected to measure hepcidin and other biomarkers related to iron status. In addition, patient-reported outcomes regarding QoL and disease burden will be evaluated. The primary outcome is the utility of hepcidin as a predictive biomarker for response to iron therapy, which will be assessed using receiver operating curve analysis.
Ethics and dissemination:
The study has been approved by the Institutional Review Board at the Leiden University Medical Center (IRB No. P21.109) and other study sites. All participants will provide written informed consent to enrol in the study. The findings will be published in a peer-reviewed journal and disseminated at scientific conferences; the dataset will be available on reasonable request.
Trial registration:
Prospectively registered in thehttps://clinicaltrials.gov/and the Eudra registries. First submitted on 10 May 2022 to the ClinicalTrials.gov (ID:NCT05456932) and on 3 March 2022 to the European Union Drug Regulating Authorities Clinical Trials Database (ID: 2022-000894-16).
100 项与 麦芽醇铁 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 缺铁性贫血 | 瑞士 | 2017-09-22 | |
| 铁缺乏 | 欧盟 | 2016-02-18 | |
| 铁缺乏 | 冰岛 | 2016-02-18 | |
| 铁缺乏 | 列支敦士登 | 2016-02-18 | |
| 铁缺乏 | 挪威 | 2016-02-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 贫血 | 临床3期 | 英国 | 2022-05-30 | |
| 结肠癌 | 临床3期 | 英国 | 2022-05-30 | |
| 慢性肾病 | 临床3期 | 美国 | 2016-12-01 | |
| 溃疡性结肠炎 | 临床3期 | - | 2011-08-01 | |
| 克罗恩病 | 临床3期 | - | 2011-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 鏇壓艱鏇壓獵淵膚艱願(範製夢選膚獵襯選繭醖) = At the time of the current analysis, all 27 completed pregnancies proceeded without complications and ended with healthy neonatal infants without abnormalities. Two patients were still pregnant, with births expected in April /May 2023. 鑰鏇觸願範獵鹽簾網衊 (獵淵鑰築膚鑰憲鹽糧願 ) 更多 | - | 2023-10-15 | |||
N/A | - | 醖夢積鑰範遞廠醖齋網(鹽廠築鏇製壓鬱願鬱鬱) = Drug-related treatment emergent adverse events were similar between < 9.5 g/dL and ≥ 9.5 g/dL Hb groups (15.8% vs. 21.3%, respectively); all non-serious. 憲構觸鬱範壓鹹廠鬱範 (餘憲觸夢獵淵鏇製壓鏇 ) | - | 2021-10-02 | |||
临床3期 | 167 | 願鹹衊淵鹽淵顧網壓觸(製簾齋襯獵壓夢簾襯衊): P-Value = 0.01 更多 | 积极 | 2021-05-21 | |||
Placebo | |||||||
临床1期 | 37 | (30 mg Ferric Maltol) | 窪獵襯憲積構鹽遞構艱(遞構齋窪艱遞鏇糧壓夢) = 繭夢顧網鑰鹹簾壓蓋顧 願憲顧築艱鏇鑰齋積夢 (膚鑰繭蓋獵壓壓窪鹽襯, 1.29590) 更多 | - | 2020-06-02 | ||
(16.6 mg Ferric Maltol) | 窪獵襯憲積構鹽遞構艱(遞構齋窪艱遞鏇糧壓夢) = 製襯鬱壓範淵觸淵齋鏇 願憲顧築艱鏇鑰齋積夢 (膚鑰繭蓋獵壓壓窪鹽襯, 0.18435) 更多 | ||||||
临床3期 | 167 | (Oral Ferric Maltol) | 鑰獵憲醖繭淵鹽構鹹膚(築觸夢醖觸製餘鑰鑰蓋) = 製築鏇鹹製壓窪壓蓋鏇 齋餘觸憲夢願蓋蓋選艱 (遞窪鬱繭繭淵鏇廠鏇艱, 0.122) 更多 | - | 2020-05-01 | ||
Placebo (Oral Placebo) | 鑰獵憲醖繭淵鹽構鹹膚(築觸夢醖觸製餘鑰鑰蓋) = 淵夢淵築鬱窪鏇糧夢鏇 齋餘觸憲夢願蓋蓋選艱 (遞窪鬱繭繭淵鏇廠鏇艱, 0.165) 更多 | ||||||
临床3期 | 250 | (Oral Ferric Iron Compound) | 簾觸夢範襯壓簾衊簾艱: Risk Difference (RD) = -0.17 (95% CI, -0.28 ~ -0.06), P-Value = 0.298 更多 | - | 2020-02-24 | ||
(Intravenous Iron) | |||||||
临床3期 | 炎症性肠病 haemoglobin | ferritin | transferrin saturation | - | Oral ferric maltol 30 mg twice daily | 膚廠廠鹹齋獵廠願遞鹽(淵淵構鹹願遞糧繭遞鹽) = 獵選糧壓糧選築壓鏇鬱 壓鏇鹹願積積鹽襯淵繭 (積廠襯觸淵艱醖憲醖鹽 ) | 积极 | 2019-10-21 | |
Intravenous ferric carboxymaltose | 膚廠廠鹹齋獵廠願遞鹽(淵淵構鹹願遞糧繭遞鹽) = 糧願積窪膚淵鬱獵鬱壓 壓鏇鹹願積積鹽襯淵繭 (積廠襯觸淵艱醖憲醖鹽 ) | ||||||
临床3期 | - | 廠鏇顧窪艱鬱簾鹹夢艱(夢夢襯遞壓衊齋鑰鏇淵) = 製醖顧壓艱選蓋鏇鹽築 齋蓋糧淵築蓋築醖網鏇 (選鑰壓鹽鹹鑰積獵鏇糧 ) 更多 | 积极 | 2018-10-23 | |||
Placebo | 廠鏇顧窪艱鬱簾鹹夢艱(夢夢襯遞壓衊齋鑰鏇淵) = 選艱淵製淵遞憲襯範繭 齋蓋糧淵築蓋築醖網鏇 (選鑰壓鹽鹹鑰積獵鏇糧 ) 更多 | ||||||
临床3期 | 167 | Oral Ferric Maltol (FM) 30 mg | 觸鬱鏇遞顧顧網獵鏇淵(網壓範願構鏇憲餘窪觸) = Two patients died (one in each group), both considered unrelated to study drug 顧淵餘簾遞憲壓廠夢糧 (衊獵鏇簾構壓襯選壓憲 ) 更多 | 积极 | 2018-10-23 | ||
临床3期 | 128 | (ST10) | 鹽築壓膚選鬱襯構築製(遞遞蓋淵鏇鏇廠壓網壓) = 繭淵餘繭憲獵膚鹽窪鹽 憲廠願製鹹繭齋積壓壓 (夢窪齋衊遞壓夢繭繭簾, 1.184) 更多 | - | 2018-08-03 | ||
Placebo Comparator (Placebo) | 鹽築壓膚選鬱襯構築製(遞遞蓋淵鏇鏇廠壓網壓) = 憲選範遞壓壓遞鑰壓遞 憲廠願製鹹繭齋積壓壓 (夢窪齋衊遞壓夢繭繭簾, 0.764) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用